The major indexes suffered another week of sharp losses as Trump tariffs ramped up, shrugging off tame inflation.

Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...

Despite a rocky start for many drugmakers at the start of last year, 2024’s fourth quarter saw just two of the top 25 global ...